Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Vaccine and PD-1 Knockout T Cells in Advanced Prostate Cancer
NCT03525652Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangdong Pharmaceutical University
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pd-1 knockout t cells in prostate cancer (PCa) (3 arms), sponsored by The First Affiliated Hospital of Guangdong Pharmaceutical University. Primary endpoint: Number of participants with adverse events and dose limiting toxicities at 6 months. Status: unknown.
02
Drugs
pd-1 knockout t cells
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03525652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525652.